ImClone System's finance-meister is jumping ship, the company announced. And no, it's not your imagination--Ana Stancic's departure will make ImClone the sixth biopharma company to lose its finance chief in recent months. There's also Pfizer (which announced its new CFO yesterday [1]), Wyeth, AstraZeneca, Amgen, and Merck.

Stancic's departure will follow the entrance of new ImClone CEO John Johnson [2], who starts Monday. The company has been getting by on interim chief execs--including a three-person executive committee, which took over last year--since 2005.

- read the report [3] from The Wall Street Journal

Related Articles:
Amgen CFO walks as challenges mount
Pfizer hires on the axe man [4]